Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL508656 | 1.00 | CHRM1 (0.62) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4888549 | 0.88 | CHRM1 (0.67) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4891561 | 0.81 | CHRM1 (0.61) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL26698570 | 0.81 | CHRM1 (0.76) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL507802 | 0.78 | CHRM1 (0.72) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| Pretomanid SCHEMBL2983011 | 0.77 | CHRM1 (1.00) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL13358956 | 0.77 | CHRM1 (0.79) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| Pretomanid SCHEMBL14004006 | 0.77 | CHRM1 (1.00) | CHRM1PTGS1SLC6A2SLC6A4KCNH2 | |
| SCHEMBL4887369 | 0.77 | CHRM1 (0.51) | CHRM1ENPP2MAPTLMNAALDH1A1 | |
| SCHEMBL4887392 | 0.77 | CHRM1 (0.51) | CHRM1ENPP2MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | claimed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | CHRM1 1375/4885PTGS1 1178/4885SLC6A2 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.